Sol-Gel Technologies (SLGL) Debt Ratio (2016 - 2017)
Sol-Gel Technologies' (SLGL) quarterly Debt Ratio came in at 4.27 in Q4 2017, up 25.52% year-on-year from 3.4 in Q4 2016, and up 25.52% on a QoQ basis from 3.4 in Q4 2016.
Sol-Gel Technologies (SLGL) Debt Ratio (2016 - 2017) Analysis & Trends
Sol-Gel Technologies (SLGL) has 2 years of Debt Ratio data on file, last reported at 4.27 in Q4 2017.
- On a quarterly basis, Debt Ratio rose 25.52% year-over-year to 4.27 in Q4 2017; TTM through Dec 2017 was 4.27, a 25.52% increase from a year earlier, with the FY2017 full-year figure at 4.27, up 25.52% from the prior year.
- Debt Ratio for Q4 2017 stood at 4.27, up from 3.4 in the prior quarter.
- Over the last five years, Debt Ratio for SLGL reached as high as 4.27 in Q4 2017 and fell as low as 3.4 in Q4 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 1.41 |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 0.11 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 0.05 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Sol-Gel Technologies | 227.58 Mn | 217.44 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | 4.27 |
| Dec 31, 2016 | 3.40 |